8-K filing — Moleculin Biotech, Inc. (MBRX)
Filed: 2026-10-05 AccNo: 0001437749-26-031978 Size: 4 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Moleculin Biotech shares are trading higher after the company announced new preclinical data indicating that the antitumor activity of its lead drug candidate, Annamycin, in pancreatic cancer is partially mediated by CD8+ T cell cytotoxicity.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Moleculin Biotech Completes Patient Enrollment In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia
Moleculin Biotech, Inc. (NASDAQ:MBRX) ("Moleculin" or the "Company") today announced that it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
Moleculin Biotech announced the publication of a peer-reviewed cardiac safety analysis of Annamycin in Frontiers in Cardiovascular Medicine. A pooled analysis of five clinical trials involving 90 patients found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits, with independent evaluation by Cleveland Clinic supporting continued clinical development.
Moleculin Announces Publication Of 90-Patient Pooled Analysis Showing No Heart Toxicity With Annamycin, Including Above Standard Dose Limits